Bosnia and Herzegovina vs Thailand: Share of E. coli infections resistant to cephalosporins
Bosnia and Herzegovina
26.8%
in 2022
Thailand
33.8%
in 2022
Bosnia and Herzegovina rank
25th
Thailand rank
23rd
Share of E. coli infections resistant to cephalosporins over time
- Bosnia and Herzegovina
- Thailand
How they compare
Thailand currently reports 33.8% against 26.8% in Bosnia and Herzegovina, a difference of 7.0%.
That makes Thailand's figure about 1.3 times Bosnia and Herzegovina's.
Across all 7 years both countries report, Thailand has been ahead every year.
Bosnia and Herzegovina ranks 25th and Thailand ranks 23rd of 46 countries.
Thailand has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bosnia and Herzegovina | Thailand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 22.0% | 38.9% | 16.9% | Thailand |
| 2020s | 26.4% | 36.9% | 10.5% | Thailand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Bosnia and Herzegovina or Thailand?
- Thailand, at 33.8% against 26.8% in Bosnia and Herzegovina as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Bosnia and Herzegovina and Thailand?
- 7.0%, with Thailand ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Thailand?
- 7 years are reported by both, from 2016 to 2022.
- How do Bosnia and Herzegovina and Thailand rank globally for share of e. coli infections resistant to cephalosporins?
- Bosnia and Herzegovina ranks 25th and Thailand ranks 23rd of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).